{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:45:01Z","timestamp":1770489901504,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11739-018-1970-3","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T06:58:16Z","timestamp":1540450696000},"page":"719-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9566","authenticated-orcid":false,"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"issue":"1","key":"1970_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet\u2019s disease. Autoimmun Rev 14(1):1\u20139. \n                              https:\/\/doi.org\/10.1016\/j.autrev.2014.08.008","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1970_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/rheumatology\/keq324","volume":"50","author":"I Kone-Paut","year":"2011","unstructured":"Kone-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA, Committee P-BIE (2011) Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet\u2019s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 50(1):184\u2013188. \n                              https:\/\/doi.org\/10.1093\/rheumatology\/keq324","journal-title":"Rheumatology (Oxford)"},{"issue":"42","key":"1970_CR3","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1097\/MD.0000000000001858","volume":"94","author":"G Lopalco","year":"2015","unstructured":"Lopalco G, Lucherini OM, Vitale A, Talarico R, Lopalco A, Galeazzi M, Lapadula G, Cantarini L, Iannone F (2015) Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for Behcet\u2019s disease. Medicine (Baltimore) 94(42):e1858. \n                              https:\/\/doi.org\/10.1097\/MD.0000000000001858","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1970_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behcet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107\u2013119. \n                              https:\/\/doi.org\/10.1038\/nrrheum.2017.208","journal-title":"Nat Rev Rheumatol"},{"key":"1970_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fimmu.2017.00200","volume":"8","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Lucherini OM, Lopalco A, Venerito V, Fabiani C, Frediani B, Galeazzi M, Lapadula G, Cantarini L, Iannone F (2017) Cytokine signatures in mucocutaneous and ocular Behcet\u2019s disease. Front Immunol 8:200. \n                              https:\/\/doi.org\/10.3389\/fimmu.2017.00200","journal-title":"Front Immunol"},{"issue":"24","key":"1970_CR6","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95(24):e3863. \n                              https:\/\/doi.org\/10.1097\/MD.0000000000003863","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1970_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11739-013-1036-5","volume":"9","author":"G Emmi","year":"2014","unstructured":"Emmi G, Silvestri E, Squatrito D, D\u2019Elios MM, Ciucciarelli L, Prisco D, Emmi L (2014) Beh\u00e7et\u2019s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med 9(3):257\u2013265. \n                              https:\/\/doi.org\/10.1007\/s11739-013-1036-5","journal-title":"Intern Emerg Med"},{"issue":"2","key":"1970_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, Rigante D, Cantarini L (2017) Adalimumab effectiveness in Behcet\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36(2):451\u2013455. \n                              https:\/\/doi.org\/10.1007\/s10067-016-3417-4","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1970_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2217\/imt.14.109","volume":"7","author":"J Braun","year":"2015","unstructured":"Braun J, Kudrin A (2015) Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy 7(2):73\u201387. \n                              https:\/\/doi.org\/10.2217\/imt.14.109","journal-title":"Immunotherapy"},{"issue":"8","key":"1970_CR10","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehoj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sorensen MV, Andersen LS, Gron KL, Krogh NS, Pedersen L, Hetland ML, All Departments of Rheumatology in D (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76(8):1426\u20131431. \n                              https:\/\/doi.org\/10.1136\/annrheumdis-2016-210742","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"1970_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/annrheumdis-2017-eular.6019","volume":"76","author":"E Din\u00e7ses","year":"2017","unstructured":"Din\u00e7ses E, Esato\u011flu S, Seyahi E, Meliko\u011flu M, Fresko I, Hamuryudan V, U\u00e7ar D, \u00d6zyazgan Y, Kutlubay Z, Mat C, Yurdakul S, Hatemi G (2017) AB0558 biosimilar infliximab for Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 76(Suppl 2):1246\u20131248. \n                              https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.6019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1970_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5152\/eurjrheum.2017.16112","volume":"4","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O (2017) Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet\u2019s disease after switching from infliximab originator. Eur J Rheumatol 4(4):288\u2013290. \n                              https:\/\/doi.org\/10.5152\/eurjrheum.2017.16112","journal-title":"Eur J Rheumatol"},{"issue":"7","key":"1970_CR13","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis. J Rheumatol 31(7):1362\u20131368","journal-title":"J Rheumatol"},{"key":"1970_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sariego IG, Hong SS, Lee SY, Park W (2016) A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 18:82. \n                              https:\/\/doi.org\/10.1186\/s13075-016-0981-6","journal-title":"Arthritis Res Ther"},{"key":"1970_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W Park","year":"2016","unstructured":"Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J (2016) Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 18:25. \n                              https:\/\/doi.org\/10.1186\/s13075-016-0930-4","journal-title":"Arthritis Res Ther"},{"key":"1970_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2017.1391297","volume":"3","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Ten-year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis. Ocul Immunol Inflamm 3:1\u20136. \n                              https:\/\/doi.org\/10.1080\/09273948.2017.1391297","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1970-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-018-1970-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1970-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T12:10:52Z","timestamp":1572437452000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-018-1970-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1970"],"URL":"https:\/\/doi.org\/10.1007\/s11739-018-1970-3","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"15 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Written informed consent was obtained from all the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}